Management of acute decompensated heart failure in patients with cancer.
Fadol
Anecita
A
University of Texas M.D. Anderson Cancer Center, Houston, USA. afadol@mdanderson.org
D000208:Acute Disease; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000359:Aftercare; D000368:Aged; D000465:Algorithms; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D001943:Breast Neoplasms / Q000150:complications / Q000628:therapy; D002316:Cardiotonic Agents / Q000627:therapeutic use; D003937:Diagnosis, Differential; D005260:Female; D006333:Heart Failure / Q000139:chemically induced / Q000175:diagnosis / Q000628:therapy; D006801:Humans; D015411:Mastectomy, Modified Radical; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D009730:Nursing Assessment; D018579:Patient Selection; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D010808:Physical Examination; D015985:Precipitating Factors; D012720:Severity of Illness Index; D014665:Vasodilator Agents / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002316:Cardiotonic Agents; D000451:Mineralocorticoid Receptor Antagonists; D010726:Phosphodiesterase Inhibitors; D014665:Vasodilator Agents